{"groups":[{"description":"Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count ≥ 50 x 10⁹/L.","id":"FG000","title":"Romiplostim"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"67"}],"type":"Protocol-specified Criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"20"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Decision by Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"203"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"203"}],"type":"Received Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"79"}],"type":"Enrolled Under Protocol Supplement"},{"achievements":[{"groupId":"FG000","numSubjects":"109"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"94"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"All participants were assigned to receive weekly romiplostim.\n\nA subset of participants enrolled under a protocol supplement in the European Union (EU), Switzerland, and Turkey were enrolled into the following 2 cohorts:\n\n* bone marrow biopsy and aspirate at baseline and year 1\n* bone marrow biopsy and aspirate at baseline and year 2","recruitmentDetails":"Children with immune thrombocytopenic purpura (ITP) and platelet counts ≤ 30×10⁹/L or uncontrolled bleeding were enrolled from December 2014 to August 2016 at 66 centers in 16 countries worldwide, including Eastern Europe (44%), Western Europe (25%), and US/Canada (21%)."}